KDMN - Kadmon trades higher on FDA approval for Belumosudil in graft-versus-host disease

Stanislau Kharytanovich/iStock via Getty Images The shares of Kadmon Holdings ([[KDMN]] +18.0%) jumped higher in reaction to the marketing approval granted by the FDA for Rezurock (Belumosudil) the company’s oral treatment developed for chronic graft-versus-host disease ((cGVHD)). According to the FDA website, Rezurock 200mg tablets have been approved by the FDA. Belumosudil (KD025), a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) had been granted the priority review by the FDA for cGVHD. In March, the company announced that the regulator has extended the review period for the therapy setting an FDA action date on August 30. The extension of the review period was done to evaluate the additional information submitted by the company in response to a request made by the FDA, Kadmon said.

For further details see:

Kadmon trades higher on FDA approval for Belumosudil in graft-versus-host disease